Impact of a Food and Drug Administration (FDA) safety communication on zolpidem dosing: An observational retrospective cohort

J. L. Harward
V. B. Clinard
M. R. Jiroutek
B. H. Lingerfeldt
A. J. Muzyk

Abstract